Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation.
Iannotta R, Celentano M, Marotta S, Pedata CM, Riccardi C, Migliaccio I, Viola A, Muggianu SM, Falco C, Bovenzi D, Ferrara F, Picardi A. Iannotta R, et al. Among authors: celentano m. Leuk Res Rep. 2022 Jul 27;18:100340. doi: 10.1016/j.lrr.2022.100340. eCollection 2022. Leuk Res Rep. 2022. PMID: 35958243 Free PMC article.
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
Marchesi F, Capria S, Pedata M, Terrenato I, Ballotta L, Riccardi C, Papa E, Riemma C, Trisolini S, Celentano M, Regazzo G, Ferrara F, Mengarelli A, Picardi A. Marchesi F, et al. Among authors: celentano m. Leuk Lymphoma. 2020 Sep;61(9):2238-2241. doi: 10.1080/10428194.2020.1765238. Epub 2020 May 18. Leuk Lymphoma. 2020. PMID: 32419550 No abstract available.
Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
Annunziata M, Celentano M, Pocali B, D'Amico MR, Palmieri S, Viola A, Copia C, Falco C, Del Vecchio L, Ferrara F. Annunziata M, et al. Among authors: celentano m. Ann Hematol. 2006 Jun;85(6):394-9. doi: 10.1007/s00277-005-0058-0. Epub 2006 Mar 15. Ann Hematol. 2006. PMID: 16538502 Clinical Trial.
Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia.
Ferrara F, Palmieri S, Pollio F, Lo Pardo C, Graziano D, Celentano M, D'Amico MR, Vicari L, Izzo B, Pane F. Ferrara F, et al. Among authors: celentano m. Biol Blood Marrow Transplant. 2006 Sep;12(9):981-6. doi: 10.1016/j.bbmt.2006.05.017. Biol Blood Marrow Transplant. 2006. PMID: 16920565 Free article.
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
Palmieri S, Ferrara F, Leoni F, Ciolli S, Pollio F, D'Amico MR, Celentano M, Viola A, Vicari L, Izzo B, Pane F. Palmieri S, et al. Among authors: celentano m. Hematol Oncol. 2007 Mar;25(1):1-5. doi: 10.1002/hon.794. Hematol Oncol. 2007. PMID: 17036374
38 results